Is Erbitux Approved for KRAS Wild-Type Cancers?
Yes, Erbitux (cetuximab) is FDA-approved for specific KRAS wild-type (no mutations in the KRAS gene) metastatic colorectal cancers. It targets EGFR and is used in combination with chemotherapy for first-line treatment of KRAS exon 2 wild-type tumors, or as monotherapy after progression on other therapies. Testing for KRAS status is required before use, as the drug shows no benefit in KRAS-mutated cases.[1][2]
How Does KRAS Status Affect Erbitux Effectiveness?
KRAS wild-type tumors respond to Erbitux because the signaling pathway remains intact for EGFR inhibition. In mutated KRAS cases, the downstream pathway is constitutively active, bypassing Erbitux's effect. Clinical trials like CRYSTAL and OPUS confirmed progression-free survival benefits only in wild-type patients (e.g., 9.9 vs. 8.4 months hazard ratio 0.85).[1][3]
Which Cancers Specifically?
- Colorectal cancer: Approved for RAS (KRAS/NRAS) wild-type metastatic disease, either with FOLFIRI/irinotecan or alone post-platinum failure.
- Head and neck cancer: Approved for squamous cell carcinoma, but KRAS testing is not standard here—response relies on EGFR expression, not KRAS status.[1][2]
No approvals for other KRAS wild-type cancers like lung or pancreatic, though off-label use or trials explore this.
What Testing Is Needed Before Treatment?
Tumors must be confirmed KRAS/NRAS wild-type via FDA-approved companion diagnostics like therascreen KRAS RGQ PCR Kit. About 40% of colorectal cancers are KRAS wild-type, guiding eligibility.[1][4]
What If KRAS Is Mutated?
Erbitux is ineffective and not recommended—label explicitly contraindicates it. Alternatives include bevacizumab or regorafenib for colorectal cancer.[1][2]
Ongoing Developments or Expanded Uses?
Trials test Erbitux in other KRAS wild-type settings, like anal cancer or combinations with immunotherapy. No new major approvals since 2017 RAS expansion.[3]
[1]: FDA Erbitux Label
[2]: NCCN Colorectal Cancer Guidelines
[3]: NEJM CRYSTAL Trial
[4]: FDA Companion Diagnostics List